Home › Research › Treatments
Interview – Interview zum Thema: Neue Alzheimer-Therapien: Warum Radiolog:innen ARIA kennen müssen
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2025-10-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Neue Alzheimer-Therapien mit Anti-Amyloid-Antikörpern wie Lecanemab oder Donanemab eröffnen Betroffenen neue Chancen – stellen die Radiologie jedoch vor besondere Herausforderungen. Eine der wichtigsten: das Erkennen und Einordnen von ARIA (Amyloid-related Imaging Abnormalities), die im Zuge der Gabe von Amyloid-Antikörper-Präparaten auftreten können und mittels MRT erkannt werden. Im conrad-Vortrag „Neue Alzheimertherapien – Radiologische Begleitphänomene im Fokus“ gibt Prof. Dr. Elke Hattingen, Direktorin der Klinik für Neuroradiologie am Universitätsklinikum Frankfurt am Main, einen Überblick über die typischen MRT-Befunde, über die bildmorphologischen Verläufe und die Risikofaktoren von ARIA. Anhand vieler ARIA-Beispiele von Patient:innen mit Alzheimer-Erkrankung werden praktische Tipps für die Beurteilung der MRT-Befunde gegeben. Radiolog:innen erfahren, worauf sie bei Diagnostik, Befundung und Verlaufsbeurteilung achten müssen – und wie sie ihre Expertise optimal in das interdisziplinäre Alzheimer-Therapiemanagement einbringen können. Publication History Article published online: 23 October 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
What this study adds
Evidence grade: Low
This interview-based article explains that anti-amyloid antibody therapies such as lecanemab and donanemab offer new chances for patients but pose challenges for radiology, especially recognizing and interpreting ARIA on MRI. It is educational guidance for radiologists on imaging findings, risk factors and monitoring, not a study of treatment effectiveness.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Interview – Interview zum Thema: Neue Alzheimer-Therapien: Warum Radiolog:innen ARIA kennen müssen. (2025). RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. https://doi.org/10.1055/a-2690-4869
Vancouver
Interview – Interview zum Thema: Neue Alzheimer-Therapien: Warum Radiolog:innen ARIA kennen müssen. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2025. doi:10.1055/a-2690-4869. PMID: 41130242.
BibTeX
@article{study2025-41130242,
title = {{Interview – Interview zum Thema: Neue Alzheimer-Therapien: Warum Radiolog:innen ARIA kennen müssen}},
journal = {RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren},
year = {2025},
doi = {10.1055/a-2690-4869},
pmid = {41130242},
url = {https://doi.org/10.1055/a-2690-4869}
}
Built from the record alzhub holds for this paper, not looked up. This record has no authors, so the citation leaves them out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Elke Hattingen, Direktorin der Klinik für Neuroradiologie am Universitätsklinikum Frankfurt am Main, einen Überblick über die typischen MRT-Befunde, über die bildmorphologischen Verläufe und die Risikofaktoren von ARIA.
- Anhand vieler ARIA-Beispiele von Patient:innen mit Alzheimer-Erkrankung werden praktische Tipps für die Beurteilung der MRT-Befunde gegeben.
- Radiolog:innen erfahren, worauf sie bei Diagnostik, Befundung und Verlaufsbeurteilung achten müssen – und wie sie ihre Expertise optimal in das interdisziplinäre Alzheimer-Therapiemanagement einbringen können.
- Publication History Article published online: 23 October 2025 © 2025.
- Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Why it matters
This interview-based article explains that anti-amyloid antibody therapies such as lecanemab and donanemab offer new chances for patients but pose challenges for radiology, especially recognizing and interpreting ARIA on MRI. It is educational guidance for radiologists on imaging findings, risk factors and monitoring, not a study of treatment effectiveness.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 26 of the 93 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren) |
| Journal's citation record | 0 / 4 | RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren: journal h-index 61 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41130242) |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 26 of the 93 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1055/a-2690-4869
- PubMed: 41130242
- Original source →
- Free full text: RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
187 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.